肾易通颗粒治疗系膜增生性肾小球肾炎临床观察  

Clinical Observation on Shenyitong Granules Treating Mesentery Hyperplastic Glomerulonephritis

作　　者：徐敢风 夏滨祥 李丽琦 

机构地区：[1]黑龙江省中医院,黑龙江哈尔滨150036

出　　处：《辽宁中医杂志》2005年第8期785-786,共2页Liaoning Journal of Traditional Chinese Medicine

摘　　要：目的:观察肾易通颗粒对系膜增生性肾炎的疗效,探讨其作用机理和临床适应症。方法:采用病例对照研究,以血管紧张素转换酶抑制剂(苯那普利)为对照,将50例患者随机分为肾易通组(20例)、肾易通加苯那普利组(15例)、苯那普利组(15例)。观察血纤维蛋白原(FIB)、血脂、肾功能及尿蛋白定量等指标变化。结果:肾易通组各疗程有效率虽较苯那普利组高,但差异无显著性(P>0·05)。肾易通加苯那普利组治疗3个疗程后的疗效(100%)不仅优于苯那普利组(P<0·05),而且优于肾易通组(P<0·05)。肾易通组与肾易通加苯那普利组胆固醇(CH)、甘油三酯(TG)、血肌酐(SCr)、FIB、尿蛋白水平显著降低(P<0·05),其中CH、TG、尿蛋白水平显著低于苯那普利组(P<0·05);苯那普利组CH、TG、FIB无明显变化。结论:中药肾易通颗粒对系膜增生性肾炎患者具有疗效好、副作用少的特点,疗效与肾脏病理学改变程度有关,病变轻者疗效优于病变重者。肾易通联合血管紧张素转换酶抑制剂应用可取得更好的疗效。Objective ：To study the therapeutic effect of Shenyitong granule （SYTG）in treating mesangial proliferating glomerulonephritis（MsPGN）and to explore its therapeutic mechanism and clinical indication. Methods ： Adopting case control method, taking angiotensin - coverting enzyme inhibitor （ benazepril ） as control agent, the 50 cases of MsPGN were randomly divided into 3 groups, treated with SYTG （Group A, n = 20 ）, SYTG plus benazepriol （Group B, n = 15）and benazepriol alone （Group C, n = 15）respectively. Changes of fibrinogen, lipids, renal function and urinary protein were observed. Results ： The total effective rate in Group A was higher than that in Group C, but with insignificant difference. The total effective rate in Group B after 3 courses of treatment was 100%, which was higher than that in Group C and Group A（P〈0.05）. Levels of cholesterol（CH）, riglyceride（TG）, serum creatinine, fibrinogen and urinary protein（UP）were significantly lowered in Group A after treatment, with the levels of CII, TG and UP lower than those in Group C, while CII, TG and fibrinogen were unchanged in Group C after treatment. Conclusion ：SYTG is superior in higher efficacy and less side - effects in treating MsPGN, its effect is related with the degree of kidney pathological changes, it is more effective in treating patients with mild pathological change than in those with severe change. The outcome of combined use of SYTG and angiotensin - converting enzyme inhibitor would be better.

关 键 词：系膜增生性肾小球肾炎 肾易通 中药复方 血管紧张素转换酶抑制剂 

分 类 号：R269.923.1[医药卫生—中西医结合]